#United States #South San Francisco #Alamar Biosciences #Proteomics #Human Longevity

Human Longevity Partners with Alamar Biosciences for Proteomic Innovation

Date: August 25, 2025
Location: South San Francisco, California

Human Longevity, Inc. (HLI), recognized globally for its leadership in precision health and longevity care, has embarked on a significant collaboration with Alamar Biosciences, a company dedicated to enhancing precision proteomics for early disease detection. This partnership aims to introduce innovative proteomic testing services that are designed to push forward the scientific boundaries of human longevity.

The primary components of this collaboration involve incorporating Alamar's advanced NULISAseq™ multiplexed panels into HLI's services. The application of these panels will facilitate the profiling of human inflammation and neurological health, thus providing a robust framework for understanding and enhancing longevity. The specific panels to be utilized include:

• - NULISAseq Inflammation Panel 250: This panel delivers precise detection and ongoing monitoring of chronic inflammation, a key factor in aging and various age-related illnesses.
• - NULISAseq CNS Disease Panel 120: This tool is focused on the early identification and monitoring of critical biomarkers related to neurodegenerative disorders and other neurological conditions, providing profound insights into brain health and resilience.

By harnessing Alamar's ultra-high sensitivity proteomics platform, NULISA™, alongside HLI's decade-long expertise in integrating genomics, imaging, and multi-omics data sourced from over 10,000 clients, this collaboration promises to yield powerful tools that will significantly impact healthspan and lifespan.

Dr. Wei-Wu He, Executive Chairman of Human Longevity, expressed his enthusiasm, stating, "Proteomics is the next frontier in longevity medicine. With the addition of high-resolution protein measurements to our extensive portfolio that already includes genomics and imaging, we are progressing towards the realization of predictive and preventive healthcare. Our alliance with Alamar enables us to directly translate cutting-edge research into clinical applications, significantly benefiting our clients."

Adding to this sentiment, Dr. Yuling Luo, Founder, Chairman, and CEO of Alamar Biosciences, emphasized the importance of their collaboration with HLI. "We are genuinely proud to work alongside Human Longevity to advance the science of healthy aging. It's incredibly rewarding to see a pioneer in longevity research choose our precision proteomics platform to drive real-world applications that can enhance longevity and health."

The implementation of these panels is set to occur later this year, as part of HLI's Executive Health and 100+ Longevity precision health programs, initially available to its members. This initiative not only represents a commitment from both parties towards improving longevity science but also emphasizes their shared objective of employing AI, multi-omics, and next-generation diagnostics to foster better health outcomes.

About Human Longevity, Inc.

Founded in 2013, Human Longevity, Inc. is a biotechnology firm focused on merging genomics, artificial intelligence, and multimodal diagnostics to extend the human healthspan. Through its flagship Executive Health Program and 100+ Longevity Programs, HLI provides comprehensive, data-driven evaluations aimed at identifying and preventing diseases before symptoms are evident. To learn more about their offerings or to enroll, visit www.humanlongevity.com.

About Alamar Biosciences, Inc.

Alamar Biosciences is a privately held life sciences company committed to advancing precision proteomics to enable early disease detection. Their proprietary NULISA™ platform, in conjunction with the ARGO™ HT System, achieves unparalleled sensitivity, surpassing existing protein detection technologies. For additional information, please visit www.alamarbio.com.

For media inquiries, contact: [email protected]
Website: www.humanlongevity.com